<DOC>
	<DOCNO>NCT00212693</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ONO-2506PO patient Parkinson 's Disease</brief_summary>
	<brief_title>Controlled Study ONO-2506PO Patients With Parkinson 's Disease Japan</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . Diagnosis Parkinson 's disease 2 . Stage 2 Stage 4 revise Hoehn &amp; Yahr severity score 3 . Taking Ldopa/DCI without change dose regimen 4 . Having motor complication 5 . Other inclusion criterion specify study protocol 1 . Previous participation ONO2506PO ONO2506 protocol 2 . Previous brain surgery Parkinson 's disease 3 . Presence history serious cardiac disease 4 . Other exclusion criterion specify study protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>ONO-2506PO , Parkinson 's disease</keyword>
</DOC>